» Articles » PMID: 29116368

N-acetyl Cysteine Reverses Bio-behavioural Changes Induced by Prenatal Inflammation, Adolescent Methamphetamine Exposure and Combined Challenges

Overview
Specialty Pharmacology
Date 2017 Nov 9
PMID 29116368
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Rationale: Schizophrenia is associated with prenatal inflammation and/or postnatal stressors such as drug abuse, resulting in immune-redox dysfunction. Antioxidants may offer therapeutic benefits.

Objectives: The objective of this study is to investigate N-acetyl cysteine (NAC) as a therapeutic antioxidant to reverse schizophrenia-like bio-behavioural changes in rats exposed to maternal immune activation (MIA), adolescent methamphetamine (MA) or a combination thereof.

Methods: Sprague-Dawley offspring prenatally exposed to saline/lipopolysaccharide (LPS) received saline or MA (0.2-6 mg kg twice daily × 16 days) during adolescence and divided into LPS, MA and LPS + MA groups. Vehicle/NAC (150 mg kg × 14 days) was administered following MA/saline exposure on postnatal day 51-64. Social interaction, novel object recognition and prepulse inhibition (PPI) of startle, as well as regional brain monoamines, lipid peroxidation, plasma reactive oxygen species (ROS) and pro- and anti-inflammatory cytokines (TNF-α; IL-10), were assessed.

Results: NAC reversed LPS, MA and LPS + MA-induced anxiety-like social withdrawal behaviours, as well as MA and LPS + MA-induced deficits in recognition memory. PPI deficits were evident in MA, LPS and LPS + MA models, with NAC reversing that following LPS + MA. NAC reversed LPS, MA and LPS + MA-induced frontal cortical dopamine (DA) and noradrenaline (NA) elevations, LPS and LPS + MA-induced frontal cortical 3,4-dihydroxyphenylacetic acid (DOPAC), serotonin (5-HT) and striatal NA deficits as well as LPS + MA-induced frontal cortical 5-HT turnover. Decreased IL-10 in the LPS, MA and LPS + MA animals, and increased TNF-α in the LPS and MA animals, was reversed with NAC. NAC also reversed elevated lipid peroxidation and ROS in the LPS and LPS + MA animals.

Conclusions: Prenatal LPS, LPS + postnatal MA challenge during adolescence, and to a lesser extent MA alone, promotes schizophrenia-like bio-behavioural changes later in life that are reversed by NAC, emphasizing therapeutic potential for schizophrenia and MA-associated psychosis. The nature and timing of the dual-hit are critical.

Citing Articles

Perinatal Hypoxia and Immune System Activation in Schizophrenia Pathogenesis: Critical Considerations During COVID-19 Pandemic.

Kawikova I, Hakenova K, Lebedeva M, Kleteckova L, Jakob L, Spicka V Physiol Res. 2024; 73(S2):S615-S639.

PMID: 39589306 PMC: 11627263.


Prenatal environmental risk factors for autism spectrum disorder and their potential mechanisms.

Love C, Sominsky L, OHely M, Berk M, Vuillermin P, Dawson S BMC Med. 2024; 22(1):393.

PMID: 39278907 PMC: 11404034. DOI: 10.1186/s12916-024-03617-3.


N-acetylcysteine during critical neurodevelopmental periods prevents behavioral and neurochemical deficits in the Poly I:C rat model of schizophrenia.

Romero-Miguel D, Casquero-Veiga M, Lamanna-Rama N, Torres-Sanchez S, MacDowell K, Garcia-Partida J Transl Psychiatry. 2024; 14(1):14.

PMID: 38191622 PMC: 10774365. DOI: 10.1038/s41398-023-02652-7.


Connecting Neurobiological Features with Interregional Dysconnectivity in Social-Cognitive Impairments of Schizophrenia.

Adraoui F, Douw L, Martens G, Maas D Int J Mol Sci. 2023; 24(9).

PMID: 37175387 PMC: 10177877. DOI: 10.3390/ijms24097680.


Schizophrenia Synaptic Pathology and Antipsychotic Treatment in the Framework of Oxidative and Mitochondrial Dysfunction: Translational Highlights for the Clinics and Treatment.

De Simone G, Mazza B, Vellucci L, Barone A, Ciccarelli M, de Bartolomeis A Antioxidants (Basel). 2023; 12(4).

PMID: 37107350 PMC: 10135787. DOI: 10.3390/antiox12040975.


References
1.
Boksa P . Effects of prenatal infection on brain development and behavior: a review of findings from animal models. Brain Behav Immun. 2010; 24(6):881-97. DOI: 10.1016/j.bbi.2010.03.005. View

2.
Howes O, McCutcheon R, Owen M, Murray R . The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia. Biol Psychiatry. 2016; 81(1):9-20. PMC: 5675052. DOI: 10.1016/j.biopsych.2016.07.014. View

3.
Zhang M, Zhao Z, He L, Wan C . A meta-analysis of oxidative stress markers in schizophrenia. Sci China Life Sci. 2010; 53(1):112-124. DOI: 10.1007/s11427-010-0013-8. View

4.
Meyer U . Developmental neuroinflammation and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 42:20-34. DOI: 10.1016/j.pnpbp.2011.11.003. View

5.
Davis J, Eyre H, Jacka F, Dodd S, Dean O, McEwen S . A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis. Neurosci Biobehav Rev. 2016; 65:185-94. PMC: 4876729. DOI: 10.1016/j.neubiorev.2016.03.017. View